Clinical trial NCT05251779: A Clinical Study on the Effects of Inhalation of Volatile Oil of Cang-Ai Via the Nose on Patients With Depression
Official title: A Clinical Study on the Effects of Inhalation of Volatile Oil of Cang-Ai Via the Nose on Patients With Depression
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: EARLY_PHASE1
Conditions: Depressive Disorder
Mental Disorder in Adolescence
Keywords: Aromatic Herbs
Volatile oils
Inhalation via the nose
Lead sponsor: Yunnan University of Chinese Medicine
Sponsor class: OTHER
First posted: 2022-02-23
Enrollment: 60
Sex: ALL
Minimum age (years): 6
Maximum age (years): 28
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In this study, 60 depressed patients who meet the criteria will randomly be divided into a test group and a control group, with 30 patients in each group. The test group will be given Volatile oil of Cang-Ai (hereafter referred to as CAVO) for inhalation and the control group will be given Bergamot for inhalation. The observation indicators are that after one and two sessions of the intervention, the patients' blood pressure, heart rate, depression scale scores, and changes in functional near-infrared spectroscopy(fNIRS). This randomized controlled trial will be used to look at the clinical efficacy of CAVO in patients with depression.

Detailed description: Depression is a common psychiatric disorder characterised by persistent depressed mood, loss of interest and feelings of helplessness. Depression has the highest burden of illness of any mental illness and is the leading cause of disability. Currently, depression is usually treated with antidepressants as the first line of treatment, but because the pathophysiological mechanisms of depression are still unclear, the mechanisms of antidepressant treatment are unknown, and there is no objective way to predict efficacy, depression often requires multiple "trial and error treatments" before an effective treatment plan can be determined. Chemically synthesised drugs are widely used to treat depression, but side effects have become a bottleneck to their long-term use. As a result, natural products from medicinal plants, such as Essential oils or Volatile oils, have become research targets for the development of new drugs. Volatile oil of Cang-Ai is a component extracted from aromatic Chinese herbs such as Atractlodis Rhizoma, Herba Agastaches, Flos Caryophylli, which is commonly used clinically in the treatment of mood disorders. This study will use a randomised controlled study method. 60 patients with depression who attended the First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine from March 2022 to September 2022 will be recruited.

They will be randomly divided into a trial group and a control group, 30 patients in each group. The test group will be given Volatile oil of Cang-Ai for inhalation and the control group will be given Bergamot for inhalation. Ultimately, a number of indicators will be tested to assess the clinical efficacy of the volatile oil of Cang-Ai.

Eligibility criteria: Inclusion Criteria:

* Meeting the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) diagnostic criteria for depressive episodes.

  * Beck Depression Scale \>10; 24-item Hamilton Depression Scale (HAMD) score \>20

    * Healthy sense of smell, no allergic diseases, respiratory diseases, age 16-40 years, male or female.

      * No use of antidepressants and other psychiatric drugs or physiotherapy such as electroconvulsive shock or transcranial magnetic stimulation (TMS) for at least 1 week prior to the intervention ⑤All subjects volunteered to participate and signed an informed consent form after approval by the hospital's ethics committee

Exclusion Criteria:

* History of schizophrenia, alcohol and drug dependence strictly excluded ②Depression with a history of organic brain disease and endocrine disorders or secondary to other psychiatric disorders

  * Score \>3 on the Hamilton Depression Inventory for Suicide ④Pregnant and breastfeeding women with a history of manic or hypomanic episodes ⑤Family history of monophasic or bipolar disorder

Primary outcomes:
measure: Change from functional near-infrared spectroscopy（fNIRS) at 28 days
timeFrame: At the end of Cycle 1 (each cycle is 14 days)
measure: Change from functional near-infrared spectroscopy（fNIRS) at 28 days
timeFrame: At the end of Cycle 2 (each cycle is 14 days)
measure: 24-item Hamilton Depression Inventory scores
timeFrame: At the end of Cycle 1 (each cycle is 14 days)
measure: 24-item Hamilton Depression Inventory scores
timeFrame: At the end of Cycle 2 (each cycle is 14 days)
Secondary outcomes:
measure: Change from blood pressure
timeFrame: At the end of Cycle 1 (each cycle is 14 days)
measure: Change from blood pressure at 28 days
timeFrame: At the end of Cycle 2 (each cycle is 14 days)
measure: Change from heart rate
timeFrame: At the end of Cycle 1 (each cycle is 14 days)
measure: Change from heart rate at 28 days
timeFrame: At the end of Cycle 2 (each cycle is 14 days)
Other outcomes:
Locations:
Study officials:
References: